Chris Sagers, the James A. Thomas Professor of Law, this week wrote  in the ProMarket blog of the University of Chicago’s Stigler Center, about a remarkable private merger challenge. He argues that the case could hold promise for future enforcement directions in American antitrust law.

Separately, he was quoted in a story for Bloomberg Law about likely trends in antitrust during the coming year.

And he spoke twice with the subscription trade journal Policy and Regulation Reporter, about deals pending merger review before the Federal Trade Commission–the massive merger of pharmaceutical firms Bristol Myers and Celgene, and the tie-up of gene-sequencing firms Illumina and Pacific Biosciences.